Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Astrocytoma, IDH-Mutant
Glioblastoma, IDH-wildtype
Brain Metastases, Adult
Cervical Cancer
Colorectal Cancer
Esophageal Cancer
Esophageal Squamous Cell Carcinoma
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Head and Neck Squamous Cell Carcinoma
Melanoma
Merkel Cell Carcinoma
Microsatellite Instability-High Solid Malignant Tumor
Mismatch Repair Deficient Solid Malignant Tumor
Microsatellite Instability-High Colorectal Cancer
Mismatch Repair Deficient Colorectal Cancer
Non-small Cell Lung Cancer
Renal Cell Carcinoma
Small Cell Lung Cancer
Squamous Cell Carcinoma
Urothelial Carcinoma

Interventions

DRUG: NEO212 Oral Capsule
DRUG: Ipilimumab
DRUG: Pembrolizumab
DRUG: Nivolumab
DRUG: Regorafenib
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: FOLFIRI Protocol
DRUG: Bevacizumab

Sponsor

Neonc Technologies, Inc.